Drug ICP-192 for Bladder Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Bladder Cancer+2 MoreDrug ICP-192 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new cancer drug, ICP-192, on patients with advanced solid tumors and FGFR gene alterations. The trial has two parts, with the first part testing different doses of the drug to see what is safe and effective, and the second part expanding the study to more patients.

Eligible Conditions
  • Bladder Cancer
  • Advanced Solid Tumors
  • Bile Duct Cancer

Treatment Effectiveness

Study Objectives

5 Primary · 6 Secondary · Reporting Duration: Up to 3 years

Up to 3 years
AUC
DCR
DOR
Drug exposure
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
MTD
OBD
ORR
OS
PD biomarker
PFS
Peak concentration (Cmax)
RP2D

Trial Safety

Trial Design

1 Treatment Group

ICP-192
1 of 1

Experimental Treatment

45 Total Participants · 1 Treatment Group

Primary Treatment: Drug ICP-192 · No Placebo Group · Phase 1 & 2

ICP-192
Drug
Experimental Group · 1 Intervention: Drug ICP-192 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 3 years

Who is running the clinical trial?

Beijing InnoCare Pharma Tech Co., Ltd.Lead Sponsor
34 Previous Clinical Trials
3,110 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are tested for the FGFR gene alteration.
You have at least one measurable lesion according to the Response Evaluation Criteria of Solid Tumor, version 1.